BioNTech (NASDAQ:BNTX) Announces Earnings Results, Beats Expectations By $0.26 EPS

BioNTech (NASDAQ:BNTX) announced its earnings results on Tuesday. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.52) by $0.26, FiscalAI reports. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. The company had revenue of $136.59 million during the quarter, compared to the consensus estimate of $207.43 million. During the same period last year, the firm earned ($1.73) earnings per share. BioNTech’s revenue was down 35.4% compared to the same quarter last year.

Here are the key takeaways from BioNTech’s conference call:

• BioNTech is pivoting to a tumor‑centric, combination‑first oncology strategy with a focus on high‑incidence cancers and aims for more than 17 late‑stage/pivotal readouts through 2030 and five additional late‑stage readouts in 2026, signaling large future catalyst potential.
• Early clinical data support the approach — pumitamab Phase I‑B/II‑A showed a 46% confirmed ORR (median PFS 13.6 months, median OS 27 months) and a 71% ORR in PD‑L1 high squamous NSCLC, underpinning the ongoing global Phase III ROSETTA LUNG‑02 program.
• Gotistobart’s non‑pivotal data are encouraging — PRESERVE‑003 interim showed a 54% reduction in risk of death versus docetaxel (HR 0.46) and a 12‑month PFS of 25% vs 0, but management notes the sample is small and requires validation in the pivotal stage later this year.
• Strong balance sheet and shareholder returns — BioNTech ended Q1 with EUR 16.8 billion in cash/securities, reaffirmed 2026 guidance (EUR 2.0–2.3bn revenues) and announced an opportunistic $1 billion ADS share buyback, supporting capital allocation alongside R&D investment.
• Management plans to consolidate manufacturing (potentially exiting sites in Idar‑Oberstein, Marburg and Singapore), affecting ~1,800 positions while targeting about EUR 500 million in recurring annual savings; near‑term execution risks and one‑time charges are possible even as long‑term efficiency improves.

BioNTech Stock Down 3.9%

BioNTech stock opened at $95.50 on Wednesday. The business’s 50-day moving average price is $97.23 and its 200 day moving average price is $101.06. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The firm has a market cap of $24.15 billion, a price-to-earnings ratio of -18.23 and a beta of 1.36. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BNTX. Leerink Partners lowered BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective for the company. in a report on Monday, February 2nd. TD Cowen reduced their target price on BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $130.00 price target on shares of BioNTech in a research note on Monday, April 27th. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $133.13.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q1 EPS beat estimates: BioNTech reported adjusted EPS of ($2.26), beating the consensus ($-2.52), which reduces near-term downside vs. expectations. BioNTech Q1 press release
• Positive Sentiment: Board approved buyback of up to $1 billion — a direct capital-return action that can support the share price and signal management’s view that shares are undervalued. BioNTech to close sites in Germany, Singapore affecting 1,860 staff
• Neutral Sentiment: FY‑2026 revenue guidance given as $2.3B–$2.7B (consensus ~ $2.6B) — a range that is roughly in line with expectations but skewed toward the low end, leaving room for mixed investor interpretation. BioNTech Announces First-Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Management commentary and the full earnings-call transcript provide detail on pipeline timing and cost actions; useful for gauging how management will hit guidance and reshape operations. BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue miss: Q1 revenue was $136.6M versus expectations of ~$207.4M and down ~35% YoY — a clear sign of weakening product sales that pressures near-term cash flow and valuation. MarketBeat Q1 results summary
• Negative Sentiment: Major restructuring: BioNTech will close multiple sites (Germany, Singapore and some CureVac sites) and cut about a quarter of its workforce — up to ~1,860 roles — signaling lower near-term capacity needs and potential execution risk. BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
• Negative Sentiment: Leadership turnover: Two co‑founders have exited, raising governance and execution concerns amid the company’s reset. BioNTech to close sites in Germany, Singapore affecting 1,860 staff
• Negative Sentiment: Market reaction: Coverage notes shares sliding as vaccine sales drop and the restructuring plan takes shape, reflecting investor concern about revenue trajectory despite cost cuts. BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer owned 399,387 shares in the company, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of the business. EFG International AG acquired a new stake in BioNTech in the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd increased its stake in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the last quarter. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter worth about $167,000. Finally, Osaic Holdings Inc. lifted its stake in BioNTech by 27.3% in the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock valued at $208,000 after buying an additional 418 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.